This article is more than 5 years old. Information may no longer be current.

EyeGate reports EGP-437 did not demonstrate non-inferiority to control group

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals announced the top-line results for a phase 3 trial of EGP-437 for the treatment of noninfectious anterior segment uveitis, which did not demonstrate non-inferiority to a control group.

The treatment, delivered through the EyeGate II Drug Delivery System, showed clinical efficacy in reducing anterior chamber cell score but did not demonstrate non-inferiority to a prednisolone acetate ophthalmic solution control group. Non-inferiority was measured by the proportion of patients with an anterior cell count of zero at day 14, according to a press release from EyeGate.

“Although we are disappointed with the results of the uveitis study, we continue to review the data and assess the path forward for EGP-437. This also represents an opportunity to shift our focus toward the key clinical trials that support our innovative Ocular Bandage Gel product, which has the potential to benefit patients with corneal surface damage. We are actively enrolling for the PRK and [punctate epitheliopathy] studies, both of which are on track for announcement of top-line data in the fourth quarter of 2018,” Stephen From, president and CEO of EyeGate, said in the release.